Tevogen Bio (NASDAQ:TVGN) Now Covered by Analysts at D. Boral Capital

D. Boral Capital started coverage on shares of Tevogen Bio (NASDAQ:TVGN) in a report released on Tuesday, MarketBeat.com reports. The firm issued a buy rating and a $10.00 price target on the stock.

Tevogen Bio Stock Performance

Shares of TVGN stock opened at $1.27 on Tuesday. The company’s 50-day simple moving average is $1.35 and its two-hundred day simple moving average is $1.15. Tevogen Bio has a one year low of $0.26 and a one year high of $8.49.

Institutional Investors Weigh In On Tevogen Bio

A number of institutional investors and hedge funds have recently bought and sold shares of TVGN. Northern Trust Corp grew its position in shares of Tevogen Bio by 13.0% during the 4th quarter. Northern Trust Corp now owns 118,415 shares of the company’s stock worth $122,000 after buying an additional 13,595 shares in the last quarter. XTX Topco Ltd purchased a new stake in Tevogen Bio in the fourth quarter worth about $55,000. Barclays PLC lifted its stake in Tevogen Bio by 39.2% in the fourth quarter. Barclays PLC now owns 45,600 shares of the company’s stock worth $48,000 after acquiring an additional 12,847 shares during the period. Geode Capital Management LLC grew its holdings in Tevogen Bio by 31.2% during the 4th quarter. Geode Capital Management LLC now owns 451,851 shares of the company’s stock worth $465,000 after acquiring an additional 107,566 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in Tevogen Bio by 74.2% during the 4th quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company’s stock valued at $40,000 after purchasing an additional 16,695 shares during the period.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.